(Total Views: 839)
Posted On: 08/13/2020 5:49:05 PM
Post# of 158221
Good news on the communication front front.
I received a reply from the Washington Post write to whom I wrote (in spite of my multiple typos. (Thanks to those who sent DMs to help me out).
I received:
"Hi ****, Thanks for the note. I’ve been getting a lot of outreach from stockholders in Cytodyn – it’s a little unusual. I’ll look into this."
Also, some more mainstream coverage that is the best I've seen recently (Barron's)
"A Field Guide to Covid-19 Vaccines and Antivirals
By Al Root"
Insert-tag-herehttps://www.barrons.com/articles/a-field-guide-to-covid-19-vaccines-and-antivirals-51597352125
I received a reply from the Washington Post write to whom I wrote (in spite of my multiple typos. (Thanks to those who sent DMs to help me out).
I received:
"Hi ****, Thanks for the note. I’ve been getting a lot of outreach from stockholders in Cytodyn – it’s a little unusual. I’ll look into this."
Also, some more mainstream coverage that is the best I've seen recently (Barron's)
"A Field Guide to Covid-19 Vaccines and Antivirals
By Al Root"
Quote:
Wednesday evening, small-cap biotech company CytoDyn announced it had asked the U.S. Food and Drug Administration to grant the company’s drug, Leronlimab, an emergency-use authorization to treat mild to moderate Covid-19 cases.
Insert-tag-herehttps://www.barrons.com/articles/a-field-guide-to-covid-19-vaccines-and-antivirals-51597352125
(15)
(0)
